A ‘Revolution’ in drugging the undruggable hits a speed bump but motors on

Though Revolution Medicines Inc.’s RAS companion / SHP2 inhibitor RMC-4630 failed to show efficacy in two early-stage combination trials, the company is moving forward with the candidate, its lead asset, partnered with Sanofi SA. Mark Goldsmith, Revolution’s president, CEO and chairman joined the BioWorld Insider Podcast to discuss the challenges and progress in other experiments.